Expertise in
17
conditions

Dr. Mohammed T. Masri

Hematology
Office
200 E Ridgeway Ave Ste 400, 
Waterloo, IA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
17
conditions
Office
200 E Ridgeway Ave Ste 400, 
Waterloo, IA 

Overview

Mohammed Masri is a Hematologist practicing medicine in Waterloo, Iowa.

Dr. Masri is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Anemia, and ALK-Positive Non-Small Cell Lung Cancer.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 21 clinical trials. Dr. Masri is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MI

Hospital Affiliations

Mclaren Macomb
Intermountain Health Platte Valley Hospital
Mclaren Oakland
Good Samaritan Medical Center LLC
Trinity Health Oakland Hospital

Languages Spoken

English
Arabic

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Upper Peninsula Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Office
200 E Ridgeway Ave Ste 400, Waterloo, IA 50702
Other Locations
Community Cancer Care Specialists
1080 Harrington St Ste 202, Mount Clemens, MI 48043

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

Integrated Cancer Repository for Cancer Research
Integrated Cancer Repository for Cancer Research
Enrollment Status: Recruiting
Publish Date: June 29, 2026
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Study to Assess the Ability to Initiate Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.
A Study to Assess the Ability to Initiate Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
View 9 Less Clinical Trials

1 Total Publications

Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.
Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: November 23, 2015
Similar Doctors
Expertise in
14
conditions
Dr. William P. Fusselman
Hematology | Oncology
Expertise in
14
conditions
Dr. William P. Fusselman
Hematology | Oncology
Referral may be required

Physicians' Clinic Of Iowa PC

202 10th St SE, 
Cedar Rapids, IA 
 (47.1 miles away)
319-297-2900
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Fusselman is a Hematologist and an Oncologist practicing medicine in Cedar Rapids, Iowa. Dr. Fusselman is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Breast Cancer, Paget Disease of the Breast, and Pleuropulmonary Blastoma. Dr. Fusselman is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Cedar Valley Medical Specialists PC

3530 W 4th St, 
Waterloo, IA 
 (3.7 miles away)
319-233-2701
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Joginder Singh is a Hematologist practicing medicine in Waterloo, Iowa. Dr. Singh is highly rated in 16 conditions, according to our data. His clinical expertise encompasses ALK-Positive Non-Small Cell Lung Cancer, Non-Hodgkin Lymphoma, Gastric Lymphoma, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration. Dr. Singh is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Mercy Medical Center-Cedar Rapids

701 10th St SE, 
Cedar Rapids, IA 
 (47.4 miles away)
319-363-8303
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Deborah Wilbur is a Hematologist practicing medicine in Cedar Rapids, Iowa. Dr. Wilbur is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Waldenstrom Macroglobulinemia, Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), and Myelodysplastic Syndrome (MDS). Dr. Wilbur is currently accepting new patients.

Frequently Asked Questions about Dr. Mohammed T. Masri

How do I make an appointment with Dr. Mohammed T. Masri?

You can book an appointment with Dr. Mohammed T. Masri by calling their office at 319-272-1510. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mohammed T. Masri a top-rated expert for Chronic B-Cell Leukemia (CBCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mohammed T. Masri is classified as an Advanced expert for Chronic B-Cell Leukemia (CBCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mohammed T. Masri specialize in?

While Dr. Mohammed T. Masri is a Hematology, they have specific expertise in Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), and Anemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Mohammed T. Masri participate in research or clinical trials?

Yes. Dr. Mohammed T. Masri has published 1 articles and abstracts on conditions like Chronic B-Cell Leukemia (CBCL). You can view a list of Dr. Mohammed T. Masri's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mohammed T. Masri accept my insurance?

Dr. Mohammed T. Masri accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 319-272-1510 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Masri's expertise for a condition
ConditionClose
      View All 17 Advanced Conditions
      View All 53 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile